Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures rarely read like light fiction. Tenax Therapeutics鈥� SEC documents splice dense trial statistics, cash-burn tables and patent language into hundreds of pages that can leave even seasoned analysts searching for answers. Whether you鈥檙e tracing Phase 3 levosimendan milestones or gauging dilution risk, you need clarity fast. Stock Titan delivers Tenax Therapeutics SEC filings explained simply with objective, machine-learned context.
Open any Tenax Therapeutics annual report 10-K simplified and our AI-powered highlights surface key risk factors, R&D spend and going-concern notes in seconds. The same engine breaks down each Tenax Therapeutics quarterly earnings report 10-Q filing, flags shifts in cash runway and links management commentary to actual numbers. AG真人官方-time alerts push Tenax Therapeutics Form 4 insider transactions real-time to your dashboard, so following Tenax Therapeutics executive stock transactions Form 4 around pivotal study announcements feels effortless. Need the story behind sudden market moves? Our summary cards turn every Tenax Therapeutics 8-K material events explained into a two-minute brief.
- Compare R&D spending trends to gauge Phase 3 financing health.
- Catch Tenax Therapeutics insider trading Form 4 transactions before traditional news feeds refresh.
- Review Tenax Therapeutics proxy statement executive compensation to see how incentives align with trial endpoints.
- Dive into catalyst timelines through understanding Tenax Therapeutics SEC documents with AI.
- Export models built from Tenax Therapeutics earnings report filing analysis without combing through footnotes.
Every document arrives within minutes of posting to EDGAR, already tagged with plain-English summaries and searchable data points. Stop juggling PDFs; let our AI surface the insights that shape Tenax Therapeutics鈥� future.
Venrock-related entities and two individuals filed an amendment to Schedule 13G reporting collective beneficial ownership of 449,492 shares of Tenax Therapeutics common stock, representing 9.99% of the class as of June 30, 2025. The reported position includes a mix of common shares, pre-funded warrants and common warrants, but the warrants contain a Beneficial Ownership Blocker that prevents exercise that would raise ownership above 9.99%. Ownership is held through VHCP III, VHCP Co-Investment III and VHCP EG, with VHCP Management entities and Messrs. Shah and Koh serving managerial/voting roles.
Janus Henderson Group plc filed a Schedule 13G reporting that it may be deemed the beneficial owner of 166,666 shares of Tenax Therapeutics common stock, representing 4.0% of the class as reported. The filing states the filer has no sole voting or dispositive power and reports shared voting and shared dispositive power for 166,666 shares, indicating the position is held through collective or affiliated advisory vehicles rather than by an individual account.
The filing contains a certification that the securities were acquired and are held in the ordinary course of business and not to influence control. Item 7 identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to managed portfolios in connection with these holdings.
Tenax Therapeutics (TENX) reported interim results showing operational progress in its Phase 3 levosimendan program while funding its near-term development plan. The company held $105.5 million in cash and cash equivalents at June 30, 2025 and reported a six-month net loss of $21.3 million, contributing to an accumulated deficit of $336.1 million. Management believes existing resources are sufficient for at least the next 12 months and states they can continue operations through 2027.
The company increased R&D and G&A spending as it expanded the ongoing Phase 3 LEVEL study and prepared a second global Phase 3 trial, LEVEL-2, with planned enrollment of 230 patients expected to complete in the first half of 2026. Tenax completed a March 2025 private placement that generated gross proceeds of ~$25.0 million (net $23.2 million) and previously raised net proceeds of ~$92.3 million in August 2024 to support clinical programs. The company also has material outstanding warrants and pre-funded warrants and significant stock-based compensation expense recognized in the period.
Tenax Therapeutics has furnished a press release disclosing its financial results for the quarter ended June 30, 2025, attaching that release as Exhibit 99.1 to this Form 8-K. The company also included an interactive XBRL cover page as Exhibit 104 and reconfirmed that the press release is furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The 8-K itself does not include any numerical financial figures; readers must consult the attached press release for detailed results and metrics.
Tenax Therapeutics, Inc. (TENX) 鈥� Form 4 filing: Director Dr. June Sherie Almenoff reported the receipt of 80,000 stock options on 07/01/2025 at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. No common-stock transactions were reported. Following the grant, Dr. Almenoff now directly holds 80,000 newly issued options in addition to previously reported grants of 100,008 options (small lots dated 2022, 2023, and 2025). The filing reflects a routine equity incentive award to a non-employee director; it does not disclose any purchases or sales of TENX common shares.
Tenax Therapeutics (TENX) filed a Form 4 disclosing insider activity by director Michael H. Davidson on 1 July 2025.
- Equity grant: Davidson acquired 80,000 stock options with an exercise price of $5.75. The options become exercisable on 01-Jul-2026 and expire on 01-Jul-2035. No cash was paid at grant (price $0.00).
- Existing derivative holdings: The filing shows additional option positions of 100,000 options at $5.94, two small option lots (4 each) at $3,200 and $992, a 47,500 pre-funded warrant (strike $0.01, no expiration) and a 25,000 warrant (strike $4.50) that will lapse upon the earlier of several milestone events or 08-Aug-2029.
- Common shares: Davidson owns 2,881 shares directly after the reported transaction.
- Total derivative exposure: The table indicates 252,508 derivative securities (options + warrants) now beneficially owned.
No sales or dispositions of Tenax common stock were reported. The transactions appear to be part of routine director compensation and warrant structures related to prior financing rounds.
Tenax Therapeutics, Inc. (TENX) 鈥� Form 4 filing dated 07/03/2025
The filing reports equity incentive activity for Robyn Hunter, a director of Tenax Therapeutics. On 07/01/2025 Ms. Hunter received a new stock-option grant for 80,000 shares of common stock at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. Following this grant she directly holds:
- 80,000 options (strike $5.75; granted 07/01/2025)
- 4 options (strike $992; expiry 06/09/2032)
- 100,000 options (strike $5.94; expiry 12/10/2034)
No open-market purchases or sales of Tenax common shares are reported; all transactions involve derivative securities (stock options). The filing reflects a routine equity award to a non-employee director and does not modify direct share ownership.
FAQ
What is the current stock price of Tenax Therapeutics (TENX)?
What is the market cap of Tenax Therapeutics (TENX)?
